Moderna (NASDAQ:MRNA) Stock Price Up 8.8% – Time to Buy?

Moderna, Inc. (NASDAQ:MRNA)’s stock price rose 8.8% during trading on Tuesday . The company traded as high as $35.00 and last traded at $35.90. Approximately 3,115,410 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 12,516,600 shares. The stock had previously closed at $32.99.

Analyst Upgrades and Downgrades

MRNA has been the topic of several research analyst reports. Wolfe Research initiated coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $111.00 to $45.00 in a report on Tuesday. UBS Group cut their price objective on Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Leerink Partners cut their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $61.58.

Moderna Trading Up 8.3 %

The company has a 50 day simple moving average of $38.61 and a 200 day simple moving average of $53.82. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $13.75 billion, a PE ratio of -6.14 and a beta of 1.59.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,664 shares of company stock valued at $115,210 in the last ninety days. Insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

A number of large investors have recently modified their holdings of the business. Arkadios Wealth Advisors raised its stake in shares of Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after buying an additional 243 shares in the last quarter. Knuff & Co LLC raised its stake in shares of Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after buying an additional 244 shares in the last quarter. Stephens Inc. AR grew its holdings in shares of Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after acquiring an additional 245 shares during the period. Allworth Financial LP grew its holdings in shares of Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after acquiring an additional 281 shares during the period. Finally, Howard Capital Management Inc. grew its holdings in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after acquiring an additional 297 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.